Amicogen amends paid-in capital increase schedule
아미코젠
092040
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2559
Risk-adjusted indicator based on 2559 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Payment Date (Original): July 15, 2026
- • Payment Date (Amended): August 4, 2026
- • New Shares Listing Date (Original): August 10, 2026
- • New Shares Listing Date (Amended): September 2, 2026
- • Discount Rate for Issuance Price: 10%
AI Analysis Summary
Amicogen, Inc. announced an amendment to its paid-in capital increase schedule. The payment date for the third-party allocation has been postponed from July 15, 2026, to August 4, 2026. Consequently, the new shares listing date is also delayed from August 10, 2026, to September 2, 2026. The issuance price will be determined using a 10% discount rate based on the weighted average stock price from 3rd to 5th trading days prior to the subscription date. Upon completion, YK Bionova Holdings Co., Ltd. is expected to become the largest shareholder. The newly issued shares will be subject to a one-year lock-up period. This amendment primarily concerns a schedule change, with no alteration to the core terms of the capital increase, thus having a neutral financial impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.